ENGNW · Insider Trading
enGene Therapeutics Inc. Warrants
Every open-market purchase and sale reported by ENGNW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Lota S. Zoth | Director | A | +31,000 deriv. | — |
| 2026-06-17 | Richard M Glickman | Director | A | +31,000 deriv. | — |
| 2026-06-17 | Wouter Joustra | Director | A | +31,000 deriv. | — |
| 2026-06-17 | William Grossman | Interim Chief Medical Officer | A | +231,000 deriv. | — |
| 2026-06-17 | Gerald A Brunk | Director | A | +31,000 deriv. | — |
| 2026-06-17 | Philip Astley-Sparke | Director | A | +31,000 deriv. | — |
| 2026-06-17 | Paul J Hastings | Director | A | +31,000 deriv. | — |
| 2026-06-17 | Michael Thomas Heffernan | Director | A | +31,000 deriv. | — |
| 2026-02-03 | Ronald Harold Wilfred Cooper | CEO & President | A | +801,000 deriv. | — |
| 2026-02-03 | Alexander Julian Nichols | Chief Strategy & Ops. Ofc | A | +195,000 deriv. | — |
| 2026-02-03 | Joan Connolly | Chief Technology Officer | A | +195,000 deriv. | — |
| 2026-02-03 | Jill Buck | Chief Development Officer | A | +195,000 deriv. | — |
| 2026-02-03 | Matthew Ross Boyd | Chief Regulatory Officer | A | +195,000 deriv. | — |
| 2026-02-03 | Lee Giguere | Chief Legal Ofc. and Corp Secy | A | +195,000 deriv. | — |
| 2026-02-03 | Anthony Tzeyew Cheung | Chief Scientific Officer | A | +195,000 deriv. | — |
| 2026-02-03 | D. Ryan Daws | Chief Financial Officer | A | +220,000 deriv. | — |
| 2025-10-01 | Hussein Sweiti | Chief Medical Officer | A | +600,000 deriv. | — |
| 2025-07-14 | Matthew Ross Boyd | Chief Regulatory Officer | A | +100,000 deriv. | — |
| 2025-07-10 | Jill Buck | Chief Development Officer | A | +100,000 deriv. | — |
| 2025-07-10 | Philip Astley-Sparke | Director | A | +45,000 deriv. | — |
| 2025-07-10 | William Grossman | Director | A | +45,000 deriv. | — |
| 2025-07-10 | Michael Thomas Heffernan | Director | A | +45,000 deriv. | — |
| 2025-06-16 | Richard M Glickman | Director | A | +22,500 deriv. | — |
| 2025-06-16 | Wouter Joustra | Director | A | +22,500 deriv. | — |
| 2025-06-16 | Jasper Bos | Director | A | +22,500 deriv. | — |
| 2025-06-16 | Lota S. Zoth | Director | A | +22,500 deriv. | — |
| 2025-06-16 | Gerald A Brunk | Director | A | +22,500 deriv. | — |
| 2025-06-16 | Paul J Hastings | Director | A | +22,500 deriv. | — |
| 2025-06-16 | Amy Pott | Chief Global Comm. Ofc. | A | +400,000 deriv. | — |
| 2025-01-31 | Anthony Tzeyew Cheung | Chief Scientific Officer | A | +250,000 deriv. | — |
| 2025-01-31 | Lee Giguere | Chief Legal Ofc. and Corp Secy | A | +250,000 deriv. | — |
| 2025-01-31 | Alexander Julian Nichols | Chief Strategy & Ops. Ofc | A | +250,000 deriv. | — |
| 2025-01-31 | Ronald Harold Wilfred Cooper | CEO & President | A | +850,000 deriv. | — |
| 2025-01-31 | Raj Som Pruthi | Chief Medical Officer | A | +280,000 deriv. | — |
| 2025-01-31 | D. Ryan Daws | Chief Financial Officer | A | +280,000 deriv. | — |
| 2024-11-01 | Forbion Growth Management B.V. | 10%+ Owner | Buy | +1,123,594 | +$10.00M |
| 2024-10-22 | Anthony Tzeyew Cheung | Chief Scientific Officer | A | +100,000 deriv. | — |
| 2024-10-22 | Joan Connolly | Chief Technology Officer | A | +210,000 deriv. | — |
| 2024-10-18 | Forbion Growth Management B.V. | 10%+ Owner | Buy | +941,266 | +$6.03M |
| 2024-10-01 | Ronald Harold Wilfred Cooper | Chief Executive Officer | Buy | +10,000 | +$57.00K |
| 2024-07-25 | Raj Som Pruthi | Chief Medical Officer | A | +110,000 deriv. | — |
| 2024-07-24 | Ronald Harold Wilfred Cooper | Chief Executive Officer | A | +1,250,000 deriv. | — |
| 2024-06-18 | Wouter Joustra | Director | A | +40,000 deriv. | — |
| 2024-06-18 | Lota S. Zoth | Director | A | +20,000 deriv. | — |
| 2024-06-18 | Gerald A Brunk | Director | A | +20,000 deriv. | — |
| 2024-06-18 | Richard M Glickman | Director | A | +20,000 deriv. | — |
| 2024-06-18 | Jasper Bos | Director | A | +20,000 deriv. | — |
| 2024-06-18 | Paul J Hastings | Director | A | +40,000 deriv. | — |
| 2024-05-29 | Richard M Glickman | Director | M | +120 | +$107 |
| 2024-04-22 | De Solidarite Des Travailleurs Du Quebec Fonds | 10%+ Owner | Sell | −52,529 | −$787.98K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Forbion Growth Management B.V. | 10%+ Owner | 6,798,362 | $1.56M |
| Anthony Tzeyew Cheung | Chief Scientific Officer | 102,873 | $23.65K |
| Gerald A Brunk | Director | 44,647 | $10.26K |
| Richard M Glickman | Director | 24,675 | $5.67K |
| Ronald Harold Wilfred Cooper | CEO & President | 10,000 | $2.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENGNW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.